Charity joins biotech firm to further inhibitors

摘要

Cancer Research Technology has announced an agreement with Cephalon Inc in the development of small molecule inhibitors of the Protein Kinase C superfamiiy. Under the agreement, Cephalon will contribute significant resources towards the progression of lead compounds - discovered at CRTs Discovery Laboratories - through to pre-clinical candidates. CRT will be entitled to significant upfront and milestone payments and royalties on sales on any products.